Steadybase.

Burning Rock Biotech Ltd.

Website LinkedIn
  • BNR · Nasdaq
  • Services-Medical Laboratories
  • Guangzhou, Guangdong, China
  • CIK 0001792267

Updated from SEC filings through

Top things to know

Executives

Burning Rock Biotech Ltd is a U.S. public company in services-medical laboratories (SIC 8071), headquartered in Guangzhou, Guangdong, China. It trades as BNR on Nasdaq. Revenue was $77.2M in the fiscal year ending December 31, 2025, +9.2% from the year before.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $77.2M
20-F, 2026-04-28
$70.7M
20-F, 2025-04-29
$75.7M
20-F, 2024-04-29
$81.7M
20-F, 2023-04-20
$79.7M
20-F, 2022-04-29
Operating income -$7.8M
20-F, 2026-04-28
-$49.0M
20-F, 2025-04-29
-$94.3M
20-F, 2024-04-29
-$142M
20-F, 2023-04-20
-$125M
20-F, 2022-04-29
SG&A $41.7M
20-F, 2026-04-28
$62.0M
20-F, 2025-04-29
$96.6M
20-F, 2024-04-29
$136M
20-F, 2023-04-20
$124M
20-F, 2022-04-29
Net income -$7.9M
20-F, 2026-04-28
-$47.5M
20-F, 2025-04-29
-$92.1M
20-F, 2024-04-29
-$141M
20-F, 2023-04-20
-$125M
20-F, 2022-04-29

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Xiaozhi Hu Senior Director in Finance Form 3, March 17, 2026

What Burning Rock Biotech Ltd does

We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Reportable segments 3 (period ending December 31, 2025) 20-F, April 28, 2026
Auditor Ernst & Young Hua Ming LLP (Shanghai, the People’s Republic of China) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
June 26, 2026 Yusheng Han
Director
Buy 731,410 $6.2M Form 4, July 2, 2026
March 31, 2026 Yusheng Han
Director
Buy 314,870 $5.5M Form 4, April 2, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Burning Rock Biotech Ltd

What does Burning Rock Biotech Ltd do?
In its own words, from Item 1 of its 10-K: "We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model."
What is Burning Rock Biotech Ltd's revenue?
$77.2M for the fiscal year ending December 31, 2025, from its 20-F filed April 28, 2026.
Is Burning Rock Biotech Ltd profitable?
Burning Rock Biotech Ltd reported net income of -$7.9M for the fiscal year ending December 31, 2025.
Where is Burning Rock Biotech Ltd headquartered?
Guangzhou, Guangdong, China.
What is Burning Rock Biotech Ltd's stock ticker?
BNR on Nasdaq.
What industry is Burning Rock Biotech Ltd in?
Services-Medical Laboratories, SIC code 8071.
What is Burning Rock Biotech Ltd's website?
brbiotech.com.
When does Burning Rock Biotech Ltd report earnings next?
November 19, 2026. Source: pg_future_events.
Is Burning Rock Biotech Ltd a public company?
Yes. Burning Rock Biotech Ltd files with the SEC under CIK 0001792267 and trades as BNR.
Who audits Burning Rock Biotech Ltd?
Ernst & Young Hua Ming LLP, Shanghai, the People’s Republic of China, as named in its latest annual report (10-K).
How many business segments does Burning Rock Biotech Ltd report?
3 reportable segments for the period ending December 31, 2025, from its 20-F filed April 28, 2026.
Have Burning Rock Biotech Ltd insiders traded stock recently?
Since March 31, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $11.6M on Forms 4 and 5. The most recent: Yusheng Han (Director) bought 731,410 shares on June 26, 2026.